Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression - Scorecard - MDSpire
Advertisement
Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression
Clinical Scorecard: Assessing the Effectiveness and Safety of Initial Immunotherapy for Metastatic Triple-Negative Breast Cancer: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials Considering PD-L1 Expression Levels
At a Glance
Category
Detail
Condition
Key Mechanisms
Immune checkpoint inhibitors (ICIs) such as pembrolizumab and toripalimab combined with chemotherapy enhance anti-tumor immune response by blocking PD-1/PD-L1 pathway.
Target Population
Care Setting
Key Highlights
ICIs combined with chemotherapy significantly improve overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone. (Clarify statistical significance of AE≥3 findings.)
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Monitor overall survival, progression-free survival, and adverse events during treatment, including specific events like neutropenia and infusion reactions.
Risks
Patient & Prescribing Data
Patients diagnosed with metastatic triple-negative breast cancer, particularly those with PD-L1 expression levels ≥1%.
Combination therapies involving ICIs and chemotherapy are recommended for improved survival outcomes.
Clinical Best Practices
Implement a multidisciplinary approach for managing treatment-related adverse events, including input from oncology, nursing, and supportive care teams.
